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 In the canonical STAT3 signaling pathway, binding of agonist to receptors activates 25 
Janus kinases which phosphorylate cytoplasmic STAT3 at tyrosine 705 (Y705). Phosphorylated 26 
STAT3 dimers accumulate in the nucleus and drive the expression of genes involved in 27 
inflammation, angiogenesis, invasion and proliferation. Here we demonstrate that human 28 
cytomegalovirus (HCMV) infection rapidly promotes nuclear localization of STAT3 in the 29 
absence of robust phosphorylation at Y705. Furthermore, infection disrupts interleukin-6 (IL6)-30 
induced phosphorylation of STAT3 and expression of a subset of IL6-induced STAT3-regulated 31 
genes including SOCS3. We show that the HCMV 72-kDa IE1 protein associates with STAT3 32 
and is necessary to localize STAT3 to the nucleus during infection. Furthermore, expression of 33 
IE1 is sufficient to disrupt IL6-induced phosphorylation of STAT3, binding of STAT3 to the 34 
SOCS3 promoter and SOCS3 gene expression. Finally, inhibition of STAT3 nuclear localization 35 
or STAT3 expression during infection is linked to diminished HCMV genome replication. Viral 36 
gene expression is also disrupted with the greatest impact seen following viral DNA synthesis. 37 
Our study identifies IE1 as a new regulator of STAT3 intracellular localization and IL6 signaling 38 




 Human cytomegalovirus (HCMV) is a human herpesvirus that infects the majority of the 41 
world population. Primary exposure results in a lifelong infection. HCMV is an opportunistic 42 
pathogen that causes serious disease in immunocompromised patients and is a leading cause of 43 
congenital birth defects (41, 44). The current FDA-approved antiviral compounds inhibit viral 44 
DNA replication and have significantly improved the management of HCMV-associated 45 
diseases. Although the use of antivirals usually resolves viremia, the compounds fail to remove 46 
the latent reservoirs of HCMV within the body. Moreover, their use is limited due to toxicity, 47 
poor oral bioavailability and the selection of antiviral resistant variants (5, 20, 35). Efforts are 48 
underway to identify additional antiviral compounds to increase treatment options. 49 
The 72-kDa immediate-early 1 (IE1) protein of HCMV is a key regulatory 50 
phosphoprotein conditionally required for viral early gene expression and replication in 51 
fibroblasts (18, 19, 42). IE1 localizes to the host cell nucleus, targeting both interchromatin 52 
compartments termed nuclear domain 10 (ND10) (2, 26, 68) and chromatin (29). Our work and a 53 
consecutive study by Huh et al. has demonstrated that IE1 forms physical complexes with 54 
STAT1 and STAT2 in the nuclei of infected cells, prevents association of STAT1, STAT2, and 55 
IRF9 with promoters of type I interferon (IFN)-stimulated genes and inhibits IFN-α-induced 56 
transcription (22, 27, 46). Consequently, IE1 disrupts type I IFN-dependent STAT signaling 57 
endowing the virus with partial resistance to the antiviral effects of IFN-α and IFN-β (22, 27, 58 
46). Notably, this activity has been subsequently shown to be conserved across IE1 homologs of 59 
the human β-herpesvirus subfamily (23). Conversely, following ectopic expression in an 60 
inducible cell model (TetR/TetR-IE1), IE1 elicited a transcriptional response dominated by the 61 
up-regulation of pro-inflammatory and immune modulatory genes normally induced by IFN-γ 62 
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(25). Although IE1-mediated gene expression proved to be independent of IFN-γ, it required the 63 
tyrosine-phosphorylated form of STAT1. Accordingly, STAT1 accumulated in the nucleus and 64 
became associated with IE1 target genes upon expression of the viral protein (25). 65 
 Another member of the STAT protein family, STAT3 is involved in regulating diverse 66 
responses. In total, four isoforms of STAT3 have been identified: full-length STAT3α and 67 
truncated STAT3β, STAT3γ, and STAT3δ (See review: 75). Although the function of the 68 
truncated isoforms is unclear, studies are beginning to suggest that they have distinct cellular 69 
activities from STAT3α (37, 72, 76). STAT3 is activated by a variety of different stimuli 70 
including interleukin-6 (IL6) and other cytokines or growth factors (1, 75). In the canonical 71 
STAT3 signaling pathway, binding of agonist to receptors activates Janus kinases (JAKs) which 72 
phosphorylate cytoplasmic STAT3 at tyrosine 705 (Y705). Phosphorylated STAT3 dimers 73 
accumulate in the nucleus and drive the expression of genes involved in inflammation, 74 
angiogenesis, invasion and proliferation (1, 75). Nuclear translocation is mediated by the 75 
importin-α and β1 heterodimer complex (9, 32). Furthermore, phosphorylation at serine 727 76 
(S727) is necessary for maximal STAT3 transcriptional activity (66, 67). Recent studies have 77 
demonstrated that STAT3 unphosphorylated at Y705 shuttles between the cytoplasm and the 78 
nucleus and is also transcriptionally active (48, 60, 70, 71). 79 
 In this study, we have determined a mechanism used by HCMV to regulate STAT3 80 
during infection. We demonstrate that HCMV IE1 is both necessary and sufficient to promote 81 
early nuclear localization of STAT3 which is predominately unphosphorylated at Y705. One 82 
functional consequence is the IE1-mediated disruption of STAT3-mediated IL6 signaling. In 83 
addition, inhibition of STAT3 nuclear localization was linked to reduced viral DNA replication 84 
and late gene expression. 85 
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MATERIALS AND METHODS 86 
Biological Reagents 87 
MRC-5 fibroblasts, ARPE-19 epithelial cells and U373 astrocytoma cells were 88 
propagated in Dulbecco's modified Eagle's medium supplemented with 7% fetal bovine serum 89 
(Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (Life Technologies). Unless 90 
otherwise stated, cells were grown until confluent, serum starved in 0.5% fetal bovine serum for 91 
2 days and then infected at a multiplicity ranging from 0.25 to 5 infectious units per cell (IU/cell) 92 
in DMEM supplemented with 0.5% FBS. In several experiments, cells were treated 24 h prior to 93 
infection with the indicated inhibitors: 15 µM curcumin (Sigma-Aldrich, St. Louis, MO), 30-150 94 
µM S3i-201 (NSC 74859) (ThermoFisher Scientific, Waltham, MA), 5 µM STATTIC (Santa 95 
Cruz), 4 µM WP1066 (Santa Cruz) or DMSO (Sigma). Compounds were replaced every 24 h. 96 
As a control for pSTAT3 and STAT3-regulatable gene expression, U-373 cells were treated with 97 
183 ng/ml of carrier free recombinant human interleukin-6 (IL6) (BioLegend, San Diego, CA) 98 
for 15 min for Western blot analysis or 45 min for gene expression studies. Studies using MRC-5 99 
cells also included recombinant human IL6 receptor alpha (IL6Rα) (R&D Systems, Minneapolis, 100 
MN). TetR-IE1 and TetR cells have been previously described (25) and were treated with 101 
doxycycline (Dox) for 0 to 72 h at a final concentration of 1 µg/ml. Viability and total cell 102 
numbers were determined with Viacount (EMD Millipore, Billerica, MA) and Gauva EasyCyte 103 
Mini Flow Cytometer (Millipore). Control siRNAs (Cell Signaling Technology), siRNA 104 
targeting importin-β1 (Life Technologies) or siRNA targeting STAT3 (On-TARGET-SMART 105 
pool) (ThermoFisher) were transfected using Lipofectamine 2000 (Life Technologies). 106 
 BAC-derived HCMV strains AD169 (ADwt) (73), ADin27F (49) and Towne wt (36) 107 
were propagated in primary fibroblasts, and Towne dlIE1 virus (27) was propagated in TetR-IE1 108 
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cells. BAC-derived HCMV clinical virus TB40/E (54) was propagated in ARPE19 epithelial 109 
cells. Viral titers were determined by an infectious units assay (40) or standard plaque assay. 110 
 111 
Analysis of Protein, DNA, and Gene Expression 112 
Preparation of cell extracts, immunoprecipitation, Western blot analysis, and 113 
immunofluorescence microscopy were completed as previously described (27, 49, 59). The 114 
antibodies used are listed below. Immunofluorescence was observed using a 63× lens in a Leica 115 
DMRX inverted microscope (Leica Microsystems, Wetzlar, Germany) equipped with a Retiga-116 
SRV digital camera and Image-Pro Plus 6.2 software (Q-Imaging, Surrey, Canada) (Figures 3, 5, 117 
and S2). Alternatively, a 60× lens in a Nikon Eclipse Ti-U inverted microscope (Nikon, Melville, 118 
NY) equipped with a CoolSNAP ES2 CCD camera (Photometrics), multifluorescent Sedat Quad 119 
ET filter set (multichroic splitter, Chroma), and NIS-Elements software (Nikon) was used for 120 
image analysis (Figures 1, 2, 6, 8, and S1). The mean fluorescent intensity of STAT3 within the 121 
nucleus and cytoplasm was obtained from an average of 20-30 cells and from at least two 122 
replicate experiments unless otherwise noted. The data is presented as nuclear to cytoplasmic 123 
ratio ± SEM. Viral DNA content and RNA expression from infected cells were determined using 124 
quantitative real-time PCR as previously described (27, 49) and primers listed below. Quantities 125 
for unknown samples were defined relative to an arbitrary standard curve consisting of 10-fold 126 
serial dilutions of one sample and completed for each primer pair. Chromatin 127 
immunoprecipitation (ChIP) coupled to qPCR was performed as described (25) using 10 µg anti-128 
STAT3 C-20 or normal rabbit IgG and primers specific to the human SOCS3 promoter or 129 
transcribed region (see below). For flow cytometry, U373 cells were dissociated from culture 130 
plates using enzyme-free cell dissociation buffer (Millipore). Cells were resuspended in PBS 131 
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with 2% BSA containing antibody-conjugate (Alexa Fluor 647) and incubated for 30 min at 4°C. 132 
Cells were washed three times using PBS with 2% BSA and then fixed with 2% 133 
paraformaldehyde. Data acquisition was performed on a BD LSR II and analyzed using FlowJo 134 
Software (Treestar, Ashland, OR). 135 
 136 
Antibodies 137 
The following antibodies were used in these studies: normal rabbit immunoglobulin G (IgG) 138 
(Sigma-Aldrich), mouse anti-FLAG M2 (Sigma-Aldrich), mouse anti-GAPDH clone 0411 139 
(Santa Cruz Biotechnology), rabbit anti-GAPDH ab9485 (Abcam), mouse anti-HA clone HA-7 140 
(Sigma-Aldrich), rabbit anti-STAT1 E-23 (Santa Cruz Biotechnology), rabbit anti-STAT2 H-190 141 
(Santa Cruz Biotechnology), mouse anti-STAT3 clone 124H6 (Cell Signaling Technology), 142 
rabbit anti-STAT3 C-20 (Santa Cruz Biotechnology), rabbit anti-pSTAT3 (Y705) (Cell 143 
Signaling Technology), rabbit anti-pSTAT3 (S727) (Cell Signaling Technology), rabbit anti-144 
H2A ab15653 (Abcam), and rabbit anti-importin β1 (Cell Signaling Technology). The antibodies 145 
against HCMV proteins were mouse anti-pUL123 clone 1B12, mouse anti-pUL122 clone 3A9, 146 
mouse anti-pTRS1, mouse anti-pUL99, mouse anti-pUL37 clone 2A1D, and mouse anti-pUL38 147 
clone 3D12 (generously provided by Dr. Tom Shenk, Princeton University) and mouse anti-148 
pUL44 (Virusys). Secondary antibodies include goat anti-mouse HRP and donkey anti-rabbit 149 
HRP (Jackson ImmunoResearch) for Western blot analysis and anti-mouse Alexa Fluor 488, 150 
anti-mouse Alexa Fluor 568, anti-mouse Alexa Fluor 594, anti-rabbit Alexa Fluor 488 (Life 151 
Technologies), and Alexa Fluor 647 conjugated to anti-CD126 (IL-6Rα) (Biolegend, San Diego, 152 
CA) for immunofluorescence. Cellular DNA was stained with 4′,6-diamidino-2-phenylindole 153 




PCR Oligonucleotides 156 
The following oligonucleotide pairs were used in these studies: IL6 (5’-157 
AGCCACTCACCTCTTCAGAACGAA-3’ and 5’-AGTGCCTCTTTGCTGCTTTCACAC-3’), 158 
SOCS3 (5’-ATTCGCCTTAAATGCTCCCTGTCC-3’ and 5’-159 
TGGCCAATACTTACTGGGCTGACA-3’) and (5’-GGCCACTCTTCAGCATCTC-3’ and 5’-160 
ATCGTACTGGTCCAGGAACTC-3’), SOCS3 promoter (5’-AGCCTTTCTCTGCTGCGAGT-161 
3’ and 5’-CCCGATTCCTGGAACTGC-3’), TUBB (5’-TATCAGCAGTACCAGGAT GC-3’ 162 
and 5’-TGAGAAGCCTGAGGTGATG-3’), GAPDH (5’-ACCCACTCCTCCACCTTTGAC-3’ 163 
and 5’-CTGTTGCTGTAGCCAAATTCGT-3’), UL123 (5’-GCCTTCCCTAAGACCACCAAT -164 
3’ and 5’-ATTTTCTGGGCATAAGCCATAATC-3’), UL122 (5’-165 
CCAGTATGCACCAGGTGTTAG-3’ and 5’-CTGGATGCCCTTGTTGTTC-3’), UL38 (5’-166 
ACGGTGCTATCGTGCTGGAGTATT-3’ and 5’-AAGACCATCACCAGGTCGTCC ATA-3’), 167 
UL99 (5’-TTCACAAGGTCCACCCACC-3’ and 5’-GTGTCCCATTCCGACTCG-3’), and 168 
UL83 (5’-TGAGCATCTCAGGTAACCTGTTG-3’ and 5’-CAGCCACGGGATCGTACTG-3’). 169 
 170 
Statistical Analysis 171 
 The data are representative of at least two independent experiments, and values are given 172 
as the mean of replicate experiments ± standard error of the mean (SEM) unless otherwise stated. 173 
For all experiments using the Student's t-test, we have determined that the variances were not 174 
different using an F-test prior to using a t-test. A significant p value (p < 0.05) is indicated by an 175 




HCMV infection localizes unphosphorylated STAT3 to the nucleus and disrupts IL6-178 
induced gene expression. Limited information is available on the impact of HCMV infection on 179 
the cellular transcription factor STAT3. To determine whether HCMV influences STAT3, we 180 
evaluated subcellular localization at 2 and 24 hpi. We infected U373 astrocytoma cells using 181 
HCMV strain AD169 (ADwt) at a multiplicity of 5 infectious units (IU) per cell in 0.5% serum. 182 
As a control, uninfected cells were treated with or without human IL6 to stimulate 183 
phosphorylation of STAT3. Reduced serum conditions allowed for more robust IL6-stimlulated 184 
responses. Cells were fixed and stained using antibodies against STAT3 and phosphorylated 185 
STAT3 (pSTAT3) at Y705. To quantify changes in localization, we determined the ratio of mean 186 
fluorescent intensities between nuclear and cytosolic staining (N/C). We detected increased 187 
STAT3 within the nuclei of infected cells at 2 hpi (N/C=2.95±0.05) and 24 hpi (N/C=6.71±0.68) 188 
as compared to uninfected cells (N/C=1.25±0.16) (Figure 1A). As expected, we observed 189 
increased nuclear localization of STAT3 (N/C=3.42±0.35) and pSTAT3 in mock plus IL6-190 
treated cells (Figure 1A). To our surprise, we detected little to no pSTAT3 within the nuclei of 191 
infected cells (Figure 1A). These data suggest that HCMV infection rapidly promotes nuclear 192 
localization of STAT3 in the absence of robust phosphorylation at Y705. 193 
 In general, phosphorylation of cytoplasmic STAT3 at Y705 occurs following cytokine 194 
and growth factor stimulation and results in STAT3 nuclear accumulation and DNA binding (1, 195 
75). We next investigated whether HCMV influences STAT3 phosphorylation during both 196 
infection and cytokine stimulation. U373 cells were infected at an MOI of 5 IU/cell and cultures 197 
were treated at the indicated times post infection with or without IL6 (Figure 1B). We evaluated 198 
steady-state protein levels using Western blot analysis on whole cell lysates isolated from a 199 
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population of cells. Compared to mock infection treated with IL6, HCMV infection suppressed 200 
IL6-induced phosphorylation of STAT3 at Y705 by 2 hpi and continued through 48 hpi (Figure 201 
1B). In contrast, phosphorylation at S727 occurred regardless of infection and was independent 202 
of IL6 stimulation (Figure 1B). At a lower MOI, we observed increased STAT3 phosphorylation 203 
at Y705 by Western blot analysis which is likely occurring within uninfected cells in the 204 
population as determined by immunofluorescence analysis (Figure S1). To determine whether 205 
the response also occurs using a clinically relevant HCMV strain, we completed the experiment 206 
using the TB40/E virus (54). Similar to AD169, TB40/E infection suppressed IL6-induced 207 
phosphorylation at Y705 but not S727 (Figure 1C). These data demonstrate that HCMV infection 208 
disrupts IL6-induced phosphorylation of STAT3 at Y705. 209 
We evaluated the impact of infection on the expression of two genes known to be 210 
regulated by STAT3, IL6 and SOCS3 (74, 75). We infected U373 cells at 1 IU/cell using ADwt 211 
virus with or without IL6 at the indicated times post infection and determined changes in gene 212 
expression using quantitative RT-PCR (qRT-PCR) relative to GAPDH RNA levels. Compared to 213 
mock control, infection significantly decreased gene expression of IL6 and SOCS3 following 214 
IL6 stimulation (Figure 1D). These data support the conclusion that HCMV infection disrupts 215 
expression of two IL6-induced STAT3-regulated genes. To exclude the possibility that 216 
disruption of IL6 signaling is a consequence of decreased IL6 receptor cell surface expression, 217 
we measured the impact of infection on IL6Rα. We infected U373 cells at 3 IU/cell and surface 218 
levels of IL6Rα were determined using flow cytometry. Compared to mock, we observed similar 219 
levels of IL6Rα during HCMV infection at 6 and 24 hpi (Figure 1E). These data rule out the 220 
possibility of HCMV-mediated loss of endogenous IL6Rα surface expression during the time of 221 
altered gene expression. 222 
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To test whether HCMV-mediated inhibition of IL6 signaling depends on STAT3 nuclear 223 
localization, we evaluated the effects on STAT3 phosphorylation after disruption of nuclear 224 
import. Nuclear translocation of STAT3 is mediated by the importin-α and β1 heterodimer 225 
complex (9, 32). We transfected U373 cells with either a control siRNA or an siRNA targeting 226 
importin-β1 expression and observed a reduction in importin-β1 levels (Figure 2A). Under these 227 
conditions, reduced importin-β1 resulted in increased pSTAT3 in IL6-treated HCMV-infected 228 
cells (Figure 2A). Furthermore, disrupting importin-β1 reduced IL6-induced STAT3 nuclear 229 
accumulation in both mock (N/C=1.27±0.11) and HCMV-infected cells (N/C=1.55±0.12) as 230 
compared to control siRNA mock (N/C=2.19±0.03) and infected (N/C=4.15±0.10) (Figure 2B). 231 
These data suggest that HCMV is promoting nuclear accumulation of STAT3 early during 232 
infection thereby moving STAT3 away from the cytosolic regulators. 233 
Changes in STAT3 phosphorylation and localization are detectable as early as 2 hpi 234 
indicating a role for HCMV virions or newly expressed proteins in manipulating STAT3. To 235 
identify the source of the activity, U373 cells were infected with either untreated ADwt or UV-236 
irradiated virus and evaluated by immunofluorescence microscopy. STAT3 nuclear localization 237 
occurred following infection with untreated (N/C=3.27±0.15) but not UV-irradiated virus 238 
(N/C=1.09±0.02) (Figure 2C). Under these conditions of UV treatment, we did not detect IE1 239 
RNA expression (Figure 2D). These data demonstrate that viral gene expression is necessary for 240 
relocalization of STAT3. 241 
 242 
HCMV IE1 promotes STAT3 nuclear accumulation and disrupts IL6-induced STAT3 243 
phosphorylation, DNA binding and target gene expression.  244 
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 HCMV immediate early protein IE1 is known to regulate both STAT1 and STAT2 (22, 245 
25, 27, 46). To determine whether IE1 expression could influence STAT3 localization, MRC-5 246 
fibroblasts were mock-infected or infected with either wild-type (wt) or an IE1-deficient virus 247 
(dlIE1) of the HCMV Towne strain at 3 PFU/cell. Using immunofluorescence microscopy, we 248 
observed increased staining of STAT3 within the nuclei of IE2-positive infected cells by 6 hpi 249 
using wt virus (N/C=1.73±0.04) but not dlIE1 (N/C=0.99±0.15) as compared to mock 250 
(N/C=1.09±0.13) (Figure 3A). This increase was also observed at both 24 (N/C=1.73±0.55) and 251 
72 hpi (N/C=2.13±0.56) (Figure 3A). At these later times, we did observe a few cells in the 252 
dlIE1 infections that had increased nuclear STAT3 staining; however, this was not significant 253 
among the population as indicated by the N/C ratio determined from a random selection of cells 254 
(n=95). These data demonstrate that IE1 is necessary for the efficient nuclear localization of 255 
STAT3 during infection. HCMV IE1 has been previously demonstrated to localize to mitotic 256 
chromatin (27). In cells undergoing mitosis in the infected population, we observed 257 
colocalization of STAT3 with DAPI-stained chromatin (Figure 3B, left and right panel). 258 
Moreover, STAT3 and IE1 colocalized in wt- but not dlIE1-infected cells (Figure 3B, right 259 
panel). To assess a possible physical interaction between IE1 and STAT3, we isolated whole cell 260 
lysates at 24 hpi and immunoprecipitated protein complexes using an antibody against IE1. 261 
Following immunoprecipitation, we detected the slower migrating STAT3α but not the smaller 262 
STAT3 isoform by Western blot analysis from TNwt-infected cells (Figure 3C). We did not 263 
observe an interaction when using an antibody against IE2 or following infection by the dlIE1 264 
virus (Figure 3C). IE1 was also specifically detected throughout the viral infectious cycle (6 to 265 
72 h) in protein complexes isolated by immunoprecipitation using a STAT3-directed antibody 266 
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(Figure 3D). These data demonstrate that HCMV IE1 associates with at least one STAT3 267 
isoform during infection.  268 
 Finally, we evaluated the functional impact of IE1 on STAT3 following IL6 stimulation. 269 
These studies were completed by adding both IL6 and soluble IL6 receptor alpha (IL6Rα) to the 270 
culture media, because MRC-5 cells are largely unresponsive to IL6 alone. Following the 271 
addition of exogenous IL6/IL6Rα, infection by wt but not dlIE1 virus resulted in reduced levels 272 
of Y705-phosphorylated STAT3 at 16 hpi as compared to mock (Figure 4A). Under these 273 
conditions in mock infected cells, IL6/IL6Rα triggered robust STAT3 DNA binding at the 274 
SOCS3 promoter and little binding at the SOCS3 transcribed region, as determined by chromatin 275 
immunoprecipitation (ChIP) assay (Figure 4B). During infection, IL6/IL6Rα-induced STAT3 276 
DNA binding was substantially diminished using wt virus but not the dlIE1 virus (Figure 4B). 277 
Concordantly, SOCS3 gene induction was significantly reduced during wt infection (Figure 4C). 278 
Infection by the dlIE1 virus altered SOCS3 expression, but to a lesser degree than wt virus 279 
(Figure 4C). Expression of HCMV IE2 was unaltered between the different conditions of 280 
infection (Figure 4C). Our results support the conclusion that HCMV IE1 binds to STAT3α and 281 
is necessary to localize STAT3 to the nucleus at early times of infection. Furthermore, 282 
expression of IE1 disrupts IL6-induced phosphorylation of STAT3, DNA association by STAT3, 283 
and SOCS3 gene induction during infection. 284 
 To determine whether IE1 expression is sufficient to mediate these changes, we induced 285 
IE1 in the absence of infection using a tetracycline repressor-regulated expression system in 286 
human fibroblasts (TetR/TetR-IE1) (25). Following induction of IE1 expression using 287 
doxycycline, we observed strong accumulation of STAT3 within the nuclei of TetR-IE1 cells 288 
(Figure 5A). STAT3 relocalization did not occur in control TetR cells (Figure 5A). By 24 to 72 h 289 
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post stimulation, greater than 90% of the IE1-positive cells contained STAT3 within the nucleus 290 
(Figure 5B), but these nuclei did not exhibit detectable pSTAT3 (Figure S3). Furthermore, 291 
STAT3 again colocalized with the viral protein and DAPI-stained mitotic chromatin upon 292 
induction of IE1 (Figure 5C). Consistent with previous studies (25), induction of IE1 expression 293 
relocalized only a fraction of STAT1 to the nucleus with delayed kinetics as compared to STAT3 294 
(Figure S2A and C) while not apparently altering the subcellular distribution of STAT2 (Figure 295 
S2B and C). We also evaluated changes in STAT3 phosphorylation upon IE1 expression. 296 
Increased expression of IE1 correlated with decreased levels of phosphorylation at Y705, while 297 
the total levels of STAT3 remained constant (Figure 5D). Under these conditions, IE1 was 298 
sufficient to suppress the levels of SOCS3 RNA (Figure 5E). Finally, induction of IE1 299 
suppressed exogenous IL6/IL6Rα-stimulated phosphorylation of STAT3 (Figure 5F and S3), 300 
SOCS3 promoter binding by STAT3 (Figure 5G) and SOCS3 expression (Figure 5H). These data 301 
indicate that expression of IE1 is sufficient to promote the nuclear accumulation of mostly 302 
unphosphorylated STAT3 inactive for sequence-specific DNA binding at the SOCS3 promoter 303 
and alter expression of the STAT3-regulated gene SOCS3. 304 
 305 
Disruption of STAT3 relocalization inhibits HCMV DNA replication. The rapid 306 
accumulation of unphosphorylated STAT3 in the nucleus during infection suggests that HCMV 307 
might utilize STAT3 for viral replication. To test this hypothesis, we evaluated the impact of 308 
chemical inhibitors of STAT3 on HCMV infection. The inhibitors included S3i-201 which 309 
inhibits STAT3 dimerization and DNA binding (53), curcumin, a natural plant polyphenol which 310 
functions, in part, by inhibiting STAT3 DNA binding (3, 7, 15, 28), STATTIC which interferes 311 
with STAT3 phosphorylation and dimerization (51), and WP1066 which blocks upstream JAK2-312 
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mediated phosphorylation (14). Initially, we tested whether the compounds would influence 313 
HCMV-mediated localization of STAT3. U373 cells were pretreated with DMSO or non-314 
cytotoxic concentrations of each compound (Figure 6A). We infected cells at a multiplicity of 5 315 
IU/cell and evaluated STAT3 by immunofluorescence microscopy. Compared to DMSO 316 
(N/C=5.30±0.12), both S3i-201 (N/C=1.26±0.10) and curcumin (N/C=1.13±0.40) treatments 317 
significantly reduced the accumulation of STAT3 in the nucleus of infected cells (Figure 6B). 318 
STATTIC treatment resulted in an intermediate phenotype (N/C=2.64±0.80) while inhibiting 319 
JAK-mediated phosphorylation using WP1066 failed to block the HCMV-mediated change in 320 
STAT3 localization (N/C=5.45±0.90) (Figure 6B). 321 
 Next, we quantified the impact of inhibiting STAT3 on HCMV replication. U373 cells 322 
were pretreated with DMSO or compound and infected at 0.25 IU/cell using ADwt virus. We 323 
quantified changes in HCMV viral DNA levels using qPCR. The addition of S3i-201 resulted in 324 
a 99.7% reduction in viral DNA levels, curcumin in a 94.0% reduction, STATTIC in an 89.5% 325 
reduction and WP1066 had no effect on DNA replication (Figure 6C). Interestingly, the percent 326 
reduction was proportional to the change in the nuclear/cytosolic ratio for STAT3 (Figure 6B). 327 
Using S3i-201, we observed the greatest decrease in DNA replication at ≥120 µM (Figure 7A). 328 
The efficacy of S3i-201 inhibition was influenced by MOI. Although still inhibiting replication, 329 
infection at 3 IU/cell resulted in approximately 71.2 % decrease in viral DNA replication (Figure 330 
7B). We also evaluated the antiviral efficacy of S3i-201 during infection of primary human 331 
foreskin fibroblasts and retinal pigmented epithelial cells. Fibroblasts and U373 cells were 332 
infected at 0.25 IU/cell using ADwt virus while epithelial cells were infected using the clinical 333 
isolate TB40/E. Chemical inhibition of STAT3 significantly reduced viral DNA replication at 72 334 
hpi in all of the cell types and viral strains (Figure 7C). Finally, we determined the impact of 335 
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STAT3 inhibition on viral titers at 96 hpi from cells treated with either DMSO or S3i-201. We 336 
observed that the addition of S3i-201 resulted in an average 2.3 log reduction in viral titers 337 
(Figure 7D). These data suggest that STAT3 nuclear localization is linked to efficient HCMV 338 
DNA replication and virus production in multiple cell types. 339 
To provide evidence that the disruption is STAT3-dependent, we knocked-down STAT3 340 
expression by transfecting U373 cells with an siRNA targeting STAT3 or control siRNA. We 341 
analyzed changes in STAT3 protein expression by Western blot and observed a reduction in 342 
STAT3 levels using the specific siRNA as compared to control (Figure 8A). Albeit reduced, we 343 
did observe STAT3 within the nucleus in cells transfected with the specific siRNA (Figure 8B). 344 
To evaluate the impact on HCMV viral DNA replication, siRNA-transfected U373 cells were 345 
infected a 0.25 IU/cell and we quantified changes in viral DNA levels using qPCR. Compared to 346 
control, we observed a 5-fold reduction in viral DNA replication upon reduced levels of STAT3 347 
(Figure 8C). These data provide additional evidence that STAT3 is necessary for fully efficient 348 
viral DNA replication. 349 
Herpesvirus gene expression is temporally regulated with kinetic classes defined as 350 
immediate early (IE), early (E), early-late (E-L) and late (L). Efficient late gene expression is 351 
dependent upon DNA replication (41). To identify the steps in replication which require STAT3, 352 
we quantified changes in viral gene expression. U373 cells were pretreated with DMSO or S3i-353 
201 and infected using ADwt virus at 0.25 IU/cell. Total RNA was harvested and viral gene 354 
expression was quantified relative to GAPDH RNA. We observed similar levels of expression 355 
for the IE and E genes UL123 (IE1) and UL38, respectively, between mock and S3i-201 356 
treatments (Figure 9A). However, beginning around 24 hpi, the addition of S3i-201 significantly 357 
decreased expression of UL122 (IE2), UL83, and UL99 (Figure 9A). We confirmed these 358 
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changes using Western blot analysis of whole cell lysates from HCMV-infected U373 cells 359 
(Figure 9B). In addition to changes in the IE2-86 kDa (pUL122) protein, we observed decreased 360 
expression of the IE2-60 kDa late isoform following S3i-201 treatment (Figure 9B). 361 
Furthermore, expression levels of two viral proteins with E-L kinetics, pTRS1 and pUL44, were 362 
also inhibited (Figure 9B) beginning at 24 hpi. These data demonstrate that inhibition of STAT3 363 
disrupts viral gene expression beginning around 24 hpi with the greatest impact seen after 48 hpi 364 
on HCMV IE2, E-L and L genes. 365 
The accumulation of E-L and L transcripts as well as UL122 is dependent on viral DNA 366 
synthesis (12, 57, 58). Furthermore, HCMV IE2, pUL44, and pTRS1 have been demonstrated to 367 
contribute to genome replication (21, 33, 34, 36, 50, 56, 65). To test the timing of STAT3’s 368 
contribution to HCMV replication, we treated U373 cells with S3i-201 at different times during 369 
infection. Cells were infected at 0.25 IU/cell using ADwt virus and treated with S3i-201 at 2 hpi 370 
or at 48 hpi for 24 h. We isolated DNA at 72 hpi and quantified viral genomes using qPCR. 371 
Consistent with previous data, S3i-201 treatment early during infection resulted in a significant 372 
decrease in viral DNA levels (Figure 9C). Conversely, treatment at 48 hpi resulted in no 373 
significant difference in viral DNA compared to control infection (Figure 9C). These data 374 
suggest that HCMV relocalizes STAT3 early to regulate early and late events during infection, 375 
including efficient viral DNA replication. 376 
 377 
DISCUSSION 378 
 We have determined that HCMV infection promotes the nuclear accumulation of STAT3 379 
that is predominantly or entirely unphosphorylated at tyrosine 705 (Y705). In the canonical 380 
pathway from uninfected cells, STAT3 is activated by a variety of different stimuli including 381 
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cytokines and growth factors, resulting in phosphorylation of Y705 (pSTAT3) and accumulation 382 
in the nucleus (1, 75). Unlike HCMV, herpesviruses that infect cells of lymphoid origin 383 
including Epstein-Barr virus (EBV) (17, 64), Kaposi’s sarcoma-associated herpesvirus (KSHV) 384 
(47), herpesvirus saimiri (HVS) (8), and varicella-zoster virus (VZV) (52) exploit the survival 385 
and oncogenic effects of pSTAT3. Beyond herpesviruses, several oncogenic viruses utilize 386 
pSTAT3 while other viruses employ mechanisms to inhibit STAT3 signaling (62, 63). Within 387 
our studies, we observed that disrupting the nuclear accumulation of STAT3 or STAT3 388 
expression inhibited HCMV infection at the stage of viral DNA replication. These studies are the 389 
first example of a virus that inhibits phosphorylation of STAT3 at Y705 yet still requires its 390 
activities for viral replication. 391 
 We have demonstrated that the HCMV IE1 protein is necessary to relocalize STAT3 to 392 
the nucleus at early times during infection, and the viral protein is also sufficient to induce 393 
nuclear STAT3 accumulation. The effects of IE1 on the subcellular distribution of STAT3 seem 394 
to be independent of phosphorylation at Y705 or cytokine stimulation. IE1 (also known as IE1-395 
72kDa or IE72) is a nuclear regulatory phosphoprotein expressed from the HCMV genome at the 396 
start of infection. IE1 has long been known to attach to human chromosomes (29), but is not 397 
considered to bind directly to DNA (43). We observed that IE1 expression promotes the 398 
association of STAT3 with mitotic chromatin yet disrupts STAT3 binding to the SOCS3 399 
promoter. Unphosphorylated STAT3 has been demonstrated to shuttle between the nucleus and 400 
the cytosol (48, 60, 70, 71), and we speculate that STAT3 nuclear export may be prevented by 401 
interactions with IE1 at cellular chromatin and/or other nuclear compartments. 402 
 One functional consequence of IE1-mediated nuclear localization of STAT3 is the 403 
suppression of IL6-induced SOCS3 gene expression. When disrupting nuclear import, we were 404 
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able to re-establish IL6-stimulated phosphorylation of STAT3 suggesting that HCMV is 405 
sequestering STAT3 away from its upstream kinases by nuclear localization. In addition, 406 
disruption of JAK signaling using the compound WP1066 failed to prevent HCMV-mediated 407 
nuclear localization or disrupt viral DNA replication. However, we cannot exclude the possibility 408 
of HCMV modulation of regulatory phosphatases. Previous studies have demonstrated that up-409 
regulation of IL6 by HCMV pUS28 resulted in pSTAT3 at Y705 (55). Consistent with these and 410 
other studies (11, 55), we observed a transient increase in IL6 expression occurring only at 2 hpi 411 
which was not affected by S3i-201 (data not shown). Furthermore, we did detect increased 412 
pSTAT3 (Y705) by Western blot when infecting most but not all of the cells in culture. Under 413 
these conditions, phosphorylation of STAT3 occurred mostly in the uninfected cells within this 414 
population. Finally, Le et al. (30) have demonstrated that HCMV infection can disrupt IFN-γ-415 
stimulated STAT3 phosphorylation starting at 24 hpi. Our studies indicate that nuclear STAT3 is 416 
predominantly unphosphorylated at Y705 in cells infected by either lab-adapted or clinical 417 
strains of HCMV. 418 
 Our data indicates that HCMV primarily utilizes unphosphorylated STAT3 to promote, 419 
either directly or indirectly, the initiation of HCMV DNA replication. Consistent with this idea, 420 
the addition of S3i-201 after 48 hpi had no effect on DNA replication. We have demonstrated 421 
that inhibition of STAT3 severely attenuates viral DNA replication, the expression of numerous 422 
viral genes, and consequently, the production of infectious viral progeny. At 24 hpi, we observed 423 
similar levels of expression for HCMV IE1, IE2 and pUL38 following STAT3 inhibition. 424 
However, we detected a substantial decrease in expression of the viral polymerase subunit, 425 
pUL44. The decrease in pUL44 levels may be attributed to decreased pTRS1 since pTRS1 426 
functions in cooperation with IE1 and IE2 to stimulate UL44 expression (10, 56). After 24 hpi, 427 
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the increase in IE2-86kDa, IE2-60kDa, pTRS1 and pUL99 levels failed to occur upon inhibiting 428 
STAT3. These changes have been shown to be dependent upon viral DNA replication (4, 13, 38, 429 
45). A similar phenotype occurred upon deletion of the HCMV protein pUL21a which, along 430 
with pUL97 kinase, negatively regulates the anaphase promoting complex (12, 13, 61). 431 
Disruption of pUL21a resulted in reduced DNA replication and late expression of a subset of 432 
proteins including IE2 and pUL99 (13).  433 
 We have demonstrated that chemical antagonists of STAT3 significantly inhibit HCMV 434 
infection. Similar observations have been made using inhibitors of STAT3 and VZV infection 435 
(52). Numerous malignancies are characterized by elevated STAT3 expression and activity (24). 436 
As a result, STAT3 inhibitors are being developed and are currently entering clinical trials as 437 
anti-cancer agents (24). Several FDA-approved compounds have been shown to inhibit STAT3 438 
activity, such as Celebrex and Sorafenib (16, 31, 69), which also inhibit HCMV replication in 439 
vitro (6, 39). Overall, our studies indicate that HCMV manipulates STAT3 to promote an 440 
environment that supports efficient viral DNA replication and implicate STAT3 as a possible 441 
target of anti-HCMV antiviral research. 442 
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FIGURE LEGENDS 694 
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Figure 1. Infection increases the levels of unphosphorylated STAT3 in the nucleus and 695 
inhibits IL6-stimulated gene expression. 696 
(A) Serum-starved U373 cells were mock-infected or infected with ADwt at 5 IU/cell in 0.5% 697 
serum. Samples were fixed at the indicated times, incubated with antibodies against STAT3 698 
(green) and pSTAT3 at Y705 (red), and counterstained for DNA with DAPI (blue). Where 699 
indicated, mock samples were treated with IL6 at 183 ng/ml. The mean fluorescent intensity of 700 
STAT3 within the nucleus and cytoplasm was obtained from an average of 20-30 cells and from 701 
at least two replicate experiments. The data is presented as nuclear to cytoplasmic ratio ± SEM. 702 
(B) Cells were infected as above and treated with IL6 or DMSO for 15 min prior to Western blot 703 
analysis using the indicated antibodies. The α- and β-STAT3 isoforms are evident upon 704 
sufficient electrophoretic separation. 705 
(C) The above experiment was repeated using the clinical isolate TB40/E. 706 
(D) Cells were infected at 1 IU/cell and treated with IL6 or DMSO for 45 min just prior to 707 
harvest at 24 and 48 hpi. Levels of the indicated mRNAs were quantified by qRT-PCR and 708 
presented relative to GAPDH. Data represent two biological replicate experiments and are 709 
presented as the mean ± SEM (∗p < 0.05). 710 
(E) Serum-starved U373 cells were infected as described in (A). Cells were fixed, stained with 711 
anti-IL6Rα antibody conjugate to Alexa-Fluor 647and analyzed using flow cytometry. As a 712 
control, cells were treated with trypsin solution for 15 min prior to antibody staining (grey) and 713 
the values represent the mean fluorescence intensity from two biological experiments. 714 
 715 
Figure 2. Nuclear accumulation of STAT3 reduces IL6-induced phosphorylation and is 716 
dependent on viral gene expression. 717 
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(A) Serum-starved U373 cells were transfected with control siRNAs or an siRNA targeting 718 
importin-β1 24 h prior to infection. Cells were mock-infected or infected with ADwt virus at 5 719 
IU/cell and treated with IL6 for 15 min prior to harvest at 24 hpi. Western blot analysis was 720 
completed using the indicated antibodies. 721 
(B) Cells were transfected, infected, and treated with IL6 as described above. At 24 hpi, cells 722 
were processed for immunofluorescence analysis using anti-STAT3 (green) and DAPI (blue). 723 
The mean fluorescent intensity of STAT3 within the nucleus and cytoplasm was obtained from 724 
an average of 20-30 cells and from at least two replicate experiments. The data is presented as 725 
nuclear to cytoplasmic ratio ± SEM. 726 
(C) U373 cells were mock-infected or infected at 5 IU/cell with either untreated or UV-irradiated 727 
ADwt virus. At 5 hpi, cells were processed for immunofluorescence analysis using anti-STAT3 728 
(green) and DAPI (blue). The mean fluorescent intensity of STAT3 within the nucleus and 729 
cytoplasm was determined as described above. 730 
(D) U373 cells were mock-infected or infected at 5 IU/cell with either untreated or UV-irradiated 731 
ADwt virus. At 5 hpi, cells were harvested and levels of IE1 mRNA was quantified by qRT-PCR 732 
and presented relative to GAPDH. Data represent two biological replicate experiments and are 733 
presented as the mean ± SEM. 734 
 735 
Figure 3. HCMV IE1 interacts with STAT3 and promotes STAT3 nuclear accumulation. 736 
(A) Growth-arrested MRC-5 cells were mock-infected or infected with wt or dlIE1 at 3 PFU/cell 737 
in 10% serum. Samples were fixed at the indicated times, incubated with antibodies against 738 
STAT3 (green) and HCMV IE2 (red), and counterstained for DNA using DAPI (blue). Scale bar, 739 
10 µm. The mean fluorescent intensity of STAT3 within the nucleus and cytoplasm was obtained 740 
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from an average of 100 cells. The data is presented as mean nuclear to cytoplasmic ratio ± 741 
standard deviation. 742 
(B) Cells were infected with wt or dlIE1 at 3 PFU/cell. Samples were fixed at 48 hpi and stained 743 
as described in (A). STAT3 staining of IE2-positive mitotic cells (left set of panels) or STAT3 744 
colocalization with IE1 at mitotic chromatin (right set of panels) is shown. Scale bars, 10 µm. 745 
(C) Cells were infected as described in (B) and extracts isolated at 24 hpi. Samples were 746 
subjected to immunoprecipitation using antibodies to IE1 or IE2 and Western blot analysis was 747 
completed on lysate and IP samples using the indicated antibodies. 748 
(D) Cells were infected as described in (B) and extracts isolated at 6 to 72 hpi. Samples were 749 
subjected to immunoprecipitation using an antibody to STAT3 or normal rabbit IgG and Western 750 
blot analysis was completed on lysates and IP samples using the indicated antibodies. 751 
 752 
Figure 4. HCMV IE1 inhibits STAT3 phosphorylation, DNA binding and target gene 753 
expression. 754 
(A) Serum-starved MRC-5 cells were infected with wt or dlIE1 at 3 PFU/cell and treated with 755 
IL6 and IL6Rα or solvent. Samples from 16 hpi were subjected to Western blot analysis using 756 
the indicated antibodies. 757 
(B) Serum-starved cells were infected as described in (A) and treated with IL6 and IL6Rα or 758 
solvent for 30 min. Samples from 16 hpi were subjected to ChIP using an antibody to STAT3 or 759 
normal rabbit IgG and primers specific for sequences in the SOCS3 promoter or transcribed 760 
region. The percentage of output to input DNA was calculated and is presented as the difference 761 
between STAT3 and normal IgG ChIPs. Data represent two biological and two technical 762 
replicates, and values are given as the mean ± standard deviation. 763 
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(C) Serum-starved cells were infected and treated as described in (A). Relative SOCS3 and IE2 764 
mRNA levels at 16 hpi were determined by qRT-PCR and presented relative to TUBB 765 
expression. Data represent three biological and two technical replicates, and values are given as 766 
the mean ± standard deviation. 767 
 768 
Figure 5. IE1 is sufficient to alter STAT3 localization and to inhibit STAT3 769 
phosphorylation, DNA binding and target gene expression. 770 
(A) TetR-IE1 and TetR cells were treated with doxycycline (Dox) for 0 to 72 h and 72 h, 771 
respectively. Samples were fixed, incubated with antibodies against IE1 (green) and STAT3 772 
(red), and counterstained for DNA using DAPI (blue). Scale bar, 10 µm. 773 
(B) The percentage of positive cell nuclei was determined from 100 randomly selected cells per 774 
sample (IE1 −, no IE1 staining above background; IE1 +, weak, mostly punctate IE1 staining; 775 
IE1 ++, strong, diffuse IE1 staining; STAT3 −, STAT3 staining mostly cytoplasmic; STAT3 +, 776 
STAT3 staining cytoplasmic and nuclear; STAT3 ++, STAT3 staining mostly nuclear). 777 
(C) TetR-IE1 and TetR cells were treated with Dox. Samples were fixed at 48 hpi and stained as 778 
described in (A). Representative mitotic cells are shown. Scale bar, 10 µm. 779 
(D) TetR-IE1 cells were treated with Dox for 0 to 72 h and Western blot analysis was completed 780 
using the indicated antibodies. 781 
(E) TetR-IE1 and TetR cells were treated with Dox for 0 to 72 h. Relative SOCS3 mRNA levels 782 
were determined by qRT-PCR and presented relative to TUBB expression and TetR at time 0 h. 783 
Data represent two biological and two technical replicates, and values are given as the mean ± 784 
standard deviation. 785 
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(F) TetR-IE1 and TetR cells were treated with Dox for 72 h and with IL6 and IL6Rα or solvent. 786 
Western blot analysis was completed using the indicated antibodies. 787 
(G) TetR-IE1 and TetR cells were treated with Dox for 72 h and with IL6 and IL6Rα or solvent 788 
for 30 min. Samples were subjected to ChIP using an antibody to STAT3 or normal rabbit IgG 789 
and primers specific for sequences in the SOCS3 promoter or transcribed region. The percentage 790 
of output to input DNA was calculated and is presented as the difference between STAT3 and 791 
normal IgG ChIPs. Data represent two biological and two technical replicates, and values are 792 
given as the mean ± standard deviation. *, below detection limit. 793 
(H) TetR and TetR-IE1 cells were treated with Dox for 72 h and with IL6 and IL6Rα or solvent. 794 
Relative SOCS3 mRNA levels were determined by qRT-PCR and presented relative to TUBB 795 
expression and TetR. Data represent three biological and two technical replicates, and values are 796 
given as the mean ± standard deviation. 797 
 798 
Figure 6. Chemical disruption of STAT3 inhibits HCMV replication. 799 
(A) U373 cells were treated with increasing concentrations of S3i-201, curcumin, STATTIC, or 800 
WP1066. At 72 h, cell viability was quantified. The data represent two biological replicate 801 
experiments and are presented as the mean ± SEM. 802 
(B) Cells were pretreated with DMSO, S3i-201, curcumin, STATTIC, or WP1066. After 24 h, 803 
cells were infected at 5 IU/cell using ADwt and processed for immunofluorescence analysis 804 
using an antibody to STAT3 (green) and the DNA stain DAPI (blue). The mean fluorescent 805 
intensity of STAT3 within the nucleus and cytoplasm was obtained from an average of 20-30 806 
cells and from at least two biological replicate experiments. The data is presented as nuclear to 807 
cytoplasmic ratio ± SEM. 808 
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(C) Cells were pretreated with drug as described above. After 24 h, cells were infected at 0.25 809 
IU/cell using ADwt. Viral genomes were quantified at 72 hpi by qPCR and normalized to 810 
cellular DNA. Data represent two biological replicates and values are given as the mean ± SEM 811 
(∗p < 0.05). 812 
 813 
Figure 7. S3i-201 inhibits HCMV replication in multiple different cell types. 814 
(A) Cells were pretreated with increasing concentrations of S3i-201. After 24 h, cells were 815 
infected at 0.25 IU/cell using ADwt. Viral genomes were quantified at 72 hpi by qPCR and 816 
normalized to cellular DNA. Data represent two biological replicates and values are given as the 817 
mean ± SEM (∗p < 0.05). 818 
(B) U373 cells were pretreated with 125 µM of S3i-201. After 24 h, cells were infected at 3 819 
IU/cell using ADwt. Viral genomes were quantified as described above. Data represent two 820 
biological replicates, and values are given as the mean ± SEM (∗p < 0.05). 821 
(C) Different cell types were pretreated with 125 µM of S3i-201. U373 and HFF cells were 822 
infected at 0.25 IU/cell using ADwt while ARPE19 cells were infected at 0.25 IU/cell using 823 
TB40/E. Viral genomes were quantified as above. Data represent two biological replicates, and 824 
values are given as the mean ± SEM (∗p < 0.05). 825 
(D) U373 cells were pretreated with drug as described above. At 24 h, cells were infected at 0.25 826 
IU/cell using ADwt. Viral titers were determined from culture supernatants obtained at 96 hpi. 827 
Data represent two biological replicates, and values are given as the mean ± SEM (∗p < 0.05). 828 
 829 
Figure 8. siRNA targeting STAT3 attenuates viral DNA replication. 830 
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(A) Serum-starved U373 cells were transfected with control siRNA or siRNA targeting STAT3. 831 
After 24 h, Western blot analysis was completed using the indicated antibodies. 832 
(B) Cells were transfected as described above. After 24 h, cells were processed for 833 
immunofluorescence analysis using anti-STAT3 (green) and DAPI (blue). The mean fluorescent 834 
intensity of STAT3 within the nucleus and cytoplasm was obtained from an average of 20-30 835 
cells and from at least two replicate experiments. The data is presented as nuclear to cytoplasmic 836 
ratio ± SEM. 837 
(C) Cells were transfected as described above. After 24 hr, cells were infected with ADwt virus 838 
at 0.25 IU/cell. Viral genomes were quantified at 72 hpi by qPCR and normalized to cellular 839 
DNA. Data represent two biological replicates and values are given as the mean ± SEM (∗p < 840 
0.05). 841 
 842 
Figure 9 STAT3 is necessary for efficient HCMV gene expression and genome replication. 843 
(A) U373 cells were pretreated with DMSO or 125 μM of S3i-201. After 24 h, cells were 844 
infected at 0.25 IU/cell using ADwt. Levels of the indicated RNAs were quantified by qRT-PCR 845 
and presented relative to GAPDH. Data represent two biological replicate experiments, and 846 
values are given as the mean ± SEM (∗p < 0.05). 847 
(B) U373 cells were pretreated with drug as described above, and after 24 h cells were infected 848 
for 2 to 72 h with ADwt at 0.25 IU/cell. Western blot analysis was completed using the indicated 849 
antibodies. 850 
(C) U373 cells were infected at 0.25 IU/cell using ADwt. Cells were then treated for 24 h with 851 
125 µM of S3I-201 at either 2 hpi or 48 hpi. After 72 hpi, viral genomes were quantified by 852 
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qPCR and normalized to cellular DNA. Data represent two biological replicates, and values are 853 
given as the mean ± SEM (∗p < 0.05). 854 









